Dr. Jeffrey L. Cummings

Research Professor, Department of Brain Health
Director, Chambers-Grundy Center for Transformative Neuroscience at UNLV
Expertise: Neuroscience, neurodegenerative diseases, Alzheimer’s Disease, drug development, clinical trials, neurotherapeutics

Biography

Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.

Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society’s Henderson Award (2006), the national Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), the American Association of Geriatric Psychiatry’s Distinguished Scientist Award (2010), and the Melvin R. Goodes Prize from the the Alzheimer's Drug Discovery Foundation (2019).

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.

Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award (2017), the International Society of CNS Drug Development’s Leadership and Achievement Award and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award (2018).

Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and he is principal investigator/director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.

Education

  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

Cleveland Clinic
Cleveland Clinic Genome Center researchers have unraveled how microglia, which perform key neuroprotective activities, also can transform and drive harmful processes such as inflammation in Alzheimer’s disease.
Practical Neurology
The Food and Drug Administration (FDA) has granted 510(k) clearance to Icobrain Aria (Icometrix, Boston, MA), a software that provides computer-assisted, automatic detection and severity grading for amyloid-related imaging abnormalities (ARIA). Icobrain Aria generates a quantitative summary report for MRI images, including severity rating scores based on the measurement and summarization of ARIA cerebral edema (ARIA-E) and ARIA cerebral microhemorrhages (ARIA-H) sites of involvement.
Imaging Technology News
On Nov. 7, 2024, the U.S. Food and Drug Administration (FDA) granted icometrix clearance for icobrain aria, the first AI software approved for detecting, measuring and grading amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new amyloid-targeting therapies. A large study, needed for FDA clearance, demonstrated that the use of icobrain aria significantly increases the accuracy of ARIA assessments by radiologists and hence allows for safer use of new amyloid-beta targeting therapies for Alzheimer’s disease patients.
PR Newswire
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today the appointment of Dr. Jeffrey Cummings, MD, ScD as Chair of its Scientific Advisory Board (SAB). Dr. Cummings, a world-renowned expert in Alzheimer's disease research and clinical trials, brings unparalleled expertise to T-Neuro Pharma's mission of advancing early Alzheimer's detection.

Articles Featuring Dr. Jeffrey L. Cummings

Josh Hawkins, UNLV
Campus News | July 3, 2024

News highlights featuring UNLV students and staff who made (refreshing) waves in the headlines.

students in spring
Campus News | May 1, 2024

News highlights starring UNLV students and faculty who made local and national headlines.